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Abstract: Post-mitotic neurons are typically terminally differentiated and in  
a quiescent status. However, in Alzheimer disease (AD), many neurons display 
ectopic re-expression of cell cycle-related proteins. Cyclin-dependent kinase 11 
(CDK11) mRNA produces a 110-kDa protein (CDK11p110) throughout the cell 
cycle, a 58-kDa protein (CDK11p58) that is specifically translated from an 
internal ribosome entry site and expressed only in the G2/M phase of the cell 
cycle, and a 46-kDa protein (CDK11p46) that is considered to be apoptosis 
specific. CDK11 is required for sister chromatid cohesion and the completion of 
mitosis. In this study, we found that the expression patterns of CDK11 vary such 
that cytoplasmic CDK11 is increased in AD cellular processes, compared to  
a pronounced nuclear expression pattern in most controls. We also investigated 
the effect of amyloid precursor protein (APP) on CDK11 expression in vitro by 
using M17 cells overexpressing wild-type APP and APP Swedish mutant 
phenotype and found increased CDK11 expression compared to empty vector. In 
addition, amyloid-β25-35 resulted in increased CDK11 in M17 cells. These data 
suggest that CDK11 may play a vital role in cell cycle re-entry in AD neurons in 
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an APP-dependent manner, thus presenting an intriguing novel function of the 
APP signaling pathway in AD. 
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INTRODUCTION 
 
Neuronal cell death is the main characteristic of Alzheimer disease (AD), 
causing clinical symptoms of senile dementia among older people manifested by 
a progressive loss of memory and other intellectual functions. The primary 
causes of cell death are unclear. It is known that genetic and environmental 
factors play an important role in AD etiology [1, 2]. 
For some time there has been a notion that altered cell cycle events in vulnerable 
neurons precede the occurrence of amyloid-β (Aβ) deposits and neurofibrillary 
tangles, the hallmarks of AD [3-6], and lead to degeneration of select neuronal 
populations in the hippocampus and other cortical brain regions. Ectopic 
expression of a number of mitosis-specific proteins has been reported in 
susceptible neurons in AD [7-12]. Recently it was found that amyloid precursor 
protein (APP) signaling processing, which results in the formation of Aβ in an 
oligomeric form, can drive neuronal cells into a new cell cycle, opening the door 
to neurodegeneration and consequently cell death [13-15].  
In mammalian cells, re-entry into the cell division cycle depends on extracellular 
signals, namely on the balance between mitogenic stimuli and differentiating 
factors [9, 16, 17]. Sequential expression, activation, and degradation of 
cyclin/cyclin-dependent kinase complexes drive the cell cycle, while their 
regulation is achieved via mechanisms of transcription, phosphorylation, 
proteolysis, and association with cyclin-dependent kinase inhibitors (CDKIs) 
[18]. G0/G1 phase transfer in the cell cycle is triggered by the presence of cyclin 
D/cdk4 and cdk6 complex [19]. When DNA replication is complete, the cyclin 
A/cdk2 complex enables transition from the S to the G2 phase (S/G2) of the cell 
cycle. For the cell to enter the G2 phase of mitosis (G2/M), degradation of cyclin 
A/cdk2 complex and expression of cyclin B, which activates cdk2, must take 
place [19].  
CDK11 regulates the G2/M phase of the cell cycle by interacting with cyclin D3 
[20]. In humans CDK11 is encoded by two highly homologous genes named 
Cdc2L1 and Cdc2L2 (cell division control 2 like). CDK11 is also known as 
PITSLRE for a conserved motif in its kinase domain and involves major 
isoforms from a number of splice variants. At least 10 CDK11 isoforms have 
been cloned in eukaryotic cells, with molecular weight varying from 46 to 
110 kDa [21]. Major isoforms are CDK11p110, CDK11p58 [22, 23], and CDK11p46 
[24]. The larger CDK11p110 is a 779-amino-acid-containing protein, representing 
the whole gene, and is ubiquitously expressed in all cell lines and constantly 
through the cell cycle [22]. CDK11p110 localizes to both splicing factor 
compartments (SFC-s) and to the nucleoplasm [25]. Another function recently 
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reported is that CDK11p110 is a Ran GTP-dependent microtubule (MT) stabilization 
factor that has an essential role in spindle assembly formation [26].  
The smaller CDK11p58 isoform is cell cycle regulated, and its synthesis occurs 
through the internal ribosome entry site (IRES), which is used only in the G2/M 
transition [27]. Although CDK11p58 and CDK11p110 share many of the same 
sequences, including the kinase domain, the two isoforms are involved in 
different regulatory pathways in eukaryotic cells. CDK11p58 is closely associated 
with cell cycle arrest and apoptosis in a kinase-dependent manner by caspase 
cleavage, producing an apoptotic kinase regulator, CDK11p46 [28-30]. Recent 
studies also revealed that CDK11 is implicated in differentiation, neuronal 
physiology, androgen receptor attenuation [31], centrosome maturation, bipolar 
spindle formation, centromere cohesion [32], and tumorigenesis [29, 33, 34].  
The recent findings that the chromatid cohesion protein regulator cohesin is 
expressed in differentiated postmitotic neurons [35] and that premature 
centromere division phenotype is a feature of AD [36-39] led us to evaluate 
CDK11 isoform expression levels in vivo in AD brain compared to age-matched 
controls. Further in vitro studies found increased expression levels of CDK11 in 
M17 cells overexpressing wild and mutant (Swedish mutation) APP phenotypes.  
 
MATERIALS AND METHODS 
 
Tissue 
Hippocampal tissue was collected at Case Western Reserve University and the 
University Hospitals of Cleveland at autopsy following IRB-approved protocols. 
Cases of AD were evaluated by a neuropathologist, met CERAD criteria, and 
underwent Braak staging. Control cases were also assigned by CERAD criteria 
and, in some cases, showed only age-related pathological structures identified 
with phosphorylated tau (AT8), and all controls were also negative for other 
neurological pathologies. Hippocampal tissue from cases of AD (n = 23, ages  
59-91 years), young controls (n = 4, ages 20-45 years), and aged-matched controls 
(n = 11, ages 53-86 years) with similar postmortem intervals (AD, 2.5-23 h; 
controls, 3.5-42 h) were fixed in methacarn (methanol: chloroform: acetic acid; 
60:30:10) or routine formalin at 4°C overnight. Following fixation, tissue was 
dehydrated through ascending ethanol, embedded in paraffin, and sectioned at 6 μm.  
 
Immunocytochemistry 
Tissue sections were deparaffinized in xylene, and hydrated through descending 
ethanol to Tris buffer (50 mM Tris, 150 mM NaCl, pH = 7.6). Endogenous 
peroxidase activity was abolished with a 30-min incubation in 3% H2O2 in 
methanol. Non-specific binding sites were blocked with a 30-min incubation in 
10% normal goat serum. Tissue sections were immunostained with two different 
rabbit antisera to CDK11 directed against the C-terminus (epitope 730-780) 
(Novus biological and Abcam) followed by the peroxidase-antiperoxidase 
method with 3,3′-diaminobenzidine as co-substrate as previously described [40]. 
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This epitope is also found on the related protein Cdc1L1. Some sections 
underwent pressure cooking using a 0.01 M anhydrous citrate buffer brought to 
maximum pressure for 10 min followed by a 10-min distilled water bath. Some 
sections were counterstained with Congo red to assess co-localization of staining 
with pathological structures. Also, adjacent sections were immunostained with 
antiserum to phosphorylated tau (AT8, Endogen) to identify the location of 
pathological structures. Control experiments included omission of primary 
antisera. Double staining experiments were performed to compare the staining 
patterns of CDK11 and glial fibrillary acidic protein (GFAP), which detects 
astroglial cells. A mouse monoclonal antibody to GFAP was used and detected 
using the alkaline phosphatase anti-alkaline phosphatase method with Fast Blue 
as chromogen. 
Using a Zeiss Axiocam and image analysis software, 3 fields of the CA1 and 
CA2 region of the hippocampus from 4 cases of AD and 4 control cases were 
imaged, and the percent area stained for CDK11 in the neuronal cell bodies and 
cellular processes determined. Student’s t-test was used to compare the AD and 
control cases. 
 
Western blot 
M17 cells were grown overexpressing wild type (APPwt) or Swedish APP 
(APPswe), or with vector only according to previously published methods [41]. 
For some experiments cells were harvested for Western blot analysis and 
homogenized with lysis buffer [50 mM Tris-HCl (pH 7.6) containing 0.02% 
sodium azide, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 150 mM 
NaCl, 1 mM phenylmethylsulfonyl fluoride, protease inhibitors cocktail from 
Roche], and centrifuged at 16 000 x g for 10 min at 4°C.  
Frozen brain tissue from AD cases (n = 12) and age-matched control cases (n = 12) 
was homogenized in lysis buffer with protease inhibitors and centrifuged at 
16 000 x g for 10 min at 4°C. The protein concentration of the cellular and brain 
supernatants was determined using the bicinchoninic acid assay method (Pierce, 
Rockford, IL, USA). Equal amounts of protein were loaded per lane and proteins 
were separated by SDS-PAGE and electroblotted onto Immobilon-P (Millipore, 
Bedford, MA, USA) by standard procedures as described before [42]. 
Antibodies used for Western blot were CDK11 (Abcam, Cambridge, MA, USA), 
1:1000, CDK11 (Novus Biologicals, Littleton, CO, USA), 1:1000 and mouse 
anti-β-actin (Chemicon, Temecula, CA, USA) 1:10 000. The same membranes 
were stripped and probed for β-actin as an internal loading control. 
Quantification of the blots was performed using a computer-assisted scanning 
system (Quantity One 4.3, Bio-Rad, USA). Results are reported as mean values 
± SEM. Significant differences between different groups were assessed by two-
tailed Student’s t-test with p < 0.05 considered statistically significant. 
 
Immunocytochemistry of APP-overexpressing cells 
Cells grown on chamber slides were fixed with paraformaldehyde, then 
permeabilized with 0.2% Triton X-100 and blocked with 10% normal goat 
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serum in PBS overnight at 4ºC. After blocking, cells were incubated with 
antibody against CDK11 for 1 h at room temperature, incubated with secondary 
antibody conjugated to Alexa Fluor 488 for 30 min at room temperature. Slides 
were mounted with medium containing DAPI to visualize nuclei and imaged 
using fluorescent microscopy. 
 
Cell culture treatment with Aβ25-35 
Immunofluorescence was performed as described [43]. Briefly M17 cells were 
cultured on chamber slides. After Aβ25-35 (40 μM) treatment for 6 h, cells were 
washed twice with PBS and then fixed with 4% paraformaldehyde for 45 min at 
room temperature. Cells were permeabilized with 0.5% Triton X-100 for 30 min, 
blocked with 10% normal goat serum for 30 min, and incubated with primary 
antibodies in PBS overnight at 4°C. After three washes with PBS, cells were 
incubated with Alexa Fluor 488-conjugated secondary antibody (Invitrogen, 
Carlsbad, CA, USA) (1:300) for 1 h at 37°C in the dark. Cells were rinsed three 
times with PBS and mounted with anti-fade medium containing DAPI (Southern 
Biotech, Birmingham, AL). All fluorescence images were captured with a Zeiss 
LSM 510 inverted fluorescence microscope (Zeiss, Oberkochen, Germany).  
 
RESULTS 
 
Immunohistochemical studies revealed different patterns of CDK11 
immunoreactivity in the hippocampus of AD cases compared to the age-matched 
controls. The majority of control cases as well as AD cases exhibited some 
cytoplasmic CDK11 immunoreactivity within pyramidal neurons of the 
hippocampus. However, significant CDK11 nuclear localization was a feature of 
11 out of the 15 controls (Fig. 1A,B) and only 1 AD case. Notably, only in the 
AD group were cellular processes a specific site of CDK11 accumulation  
(Fig. 1C,D), and this was seen in the majority of AD cases. Double-label 
immunocytochemistry with GFAP, a marker of astrocytes, revealed that the 
majority of cellular processes were not GFAP-positive, and likely were neuronal 
(Fig. 1F). There were 4 control and 5 AD cases that showed very little 
cytoplasmic or nuclear CDK11, and these cases had no distinguishing 
characteristics or correlated to age or disease severity.  
Quantification of representative AD and control cases found that an average of 
over 80% of the CDK11 staining in the hippocampus was localized to cellular 
processes in the AD cases. In the control cases, however, over 50% of the 
staining was found localized in the nuclei and soma. These differences were 
found to be statistically significant (Fig. 1E, p < 0.001). CDK11 was not 
specifically found in the pathological lesions of AD when compared with Congo 
red or tau immunohistochemistry (data not shown). 
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Fig. 1. Localization of CDK11 in hippocampal neurons from 2 representative control cases 
displaying weak cytoplasm and significant nuclear localization, arrowheads (A, B). 
CDK11, in 2 representative cases of AD, was localized to the neuronal cytoplasm and 
processes (arrow) throughout the hippocampus (C, D). Double label immunocytochemistry 
with GFAP (F, brown) revealed that the majority of CDK11 processes (F, blue stain, red 
arrows) are not glial and likely derive from neurons. Nuclei were not specifically labeled in 
nearly all the AD cases. Quantification revealed striking differences of CDK11 staining of 
the soma and cellular processes between AD (n = 4) and control (n = 4) cases. (E, *p < 0.01). 
Scale bars = 50 μm. 
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Fig. 2. Western blot analysis of frozen brain tissue revealed that only the CDK11p110 
isoform is present at higher levels in the control cases compared to AD cases (*p < 0.05). 
Data are expressed as mean ± SEM of CDK11p110, CDK11p58, and CDK11p46 protein levels 
relative to actin from AD cases (n = 12) and age-matched controls (n = 12). Representative 
lanes showing the specific detection of CDK11 are shown. 
 
 
 
Fig. 3. Representative images of CDK11 in M17 cells with empty vector or APPwt or 
APPswe overexpression (A). CDK11 expression levels were examined by Western blot (B). 
Quantification found significantly higher levels of CDK11 in cells overexpressing APP 
(mean ± SEM). * indicates significant difference between vector control and APPwt or 
APPswe cells with p < 0.05. Scale bars = 50 μm. 
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Western blot analysis of human brain samples revealed that the antibodies 
detected specific bands corresponding to CDK11p110, CDK11p58, and CDK11p46. 
Quantification found that CDK11p110 is present at higher levels in the control 
cases (p < 0.05), and representative lanes of the AD and control samples are 
shown (Fig. 2). 
CDK11 expression levels in M17 cells with empty vector or APPwt or mutant 
APP overexpression were examined using fluorescent microscopy. Both the 
APPwt and APPswe overexpressing cells displayed greater CDK11 
immunoreactivity than the cells with vector alone (Fig. 3A). While the strongest 
labeling was apparent in the nuclei, when compared to the DAPI localization, 
some CDK11 was also demonstrated in the cytoplasm. Western blot analysis of 
the cell lysates revealed the CDK11p110 isoform to be the dominant form. 
Quantification of the CDK11 levels revealed that both the APPwt and APPswe 
cells expressed significantly higher levels of CDK11.  
M17 cells were then treated with Aβ25-35 peptide for 6 h, a treatment time that 
did not cause significant cell death. Compared with untreated cells, CDK11 
localization was greatly increased throughout the cells following exposure to Aβ 
(Fig. 4). 
 
 
 
Fig. 4. Localization of CDK11 in M17 cells treated with Aβ25-35. Compared to untreated 
cells, the immunohistochemistry data show that Aβ25-35 (40 μM) treatment for 6 h induces 
upregulation of CDK11 in the neuronal cytoplasm. 
 
DISCUSSION 
 
In this study, we demonstrated that CDK11, a G2/M phase regulator of the cell 
cycle, is found in the cytoplasm and cellular processes of the pyramidal neurons 
and other cells in many cases of AD, yet in most control samples CDK11 is 
expressed at much higher levels in the nuclei. Western blot analysis confirms 
differences in CDK11p110 levels between AD and control groups, which may 
reflect the increased nuclear localization found in the normal human 
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hippocampal tissue sections. Together these data suggest mislocalization of 
CDK11 from the nuclei to the cytoplasm and processes in AD. The same 
distribution of ectopic re-expression in the AD brain (cytoplasm versus neuronal 
nuclei) has been reported for a number of cell cycle regulators such as Polo-like 
kinases, neuronal CIP-1-associated regulator of cyclin B (CARB), and p130,  
a retinoblastoma-related protein [44-46], as well as mitogenic signal 
transduction pathway components [47-49]. 
It is still under debate whether susceptible neurons arrest at some point between 
the G1 and M phases of the cell cycle. A number of studies have found 
concordance of elevated levels of cyclin/CDK levels, cyclins that control the 
G2/M transition and chromosomal instability in neuronal cells [5, 50]. 
Chromosomal instability phenotypes such as tetraploidy [51], binuclear neuronal 
cells [52], and premature centromere separation [53], which correlate to the 
G2/M phase of the cell cycle, have also been found to be increased in AD. 
The findings presented here represent a multi-faceted CDK11 function in AD.  
In vitro analysis of the effect of APP, by using cells that overexpress APPwt and 
APPswe, finds that CDK11 is increased compared to cells with vector only. 
Further, in M17 cells, treatment with Aβ peptide also results in increased 
CDK11. Yet, in cells with either APP overexpression or its AD-associated 
cleavage products, only CDK11p110 isoform was detected. APPwt and APPswe 
overexpression represents both sporadic and genetically linked AD. CDK11 
dysfunction may be vital to understanding the neuronal degeneration due to the 
fact that it is similar in the model representing sporadic disease, as this accounts 
for over 90% of cases of AD. In human disease tissue collected at the time of 
autopsy, which is often decades after disease onset, the mislocalization of 
CDK11 from the nucleus to the cytoplasm and peripheral cellular processes,  
a morphological feature not found in normal brain, suggests an abnormal cellular 
response to cellular stress via CDK11. The significant loss of CDK11p110 in the 
human brain samples of AD points to this mislocalization seen by morphological 
analysis. The cleavage of CDK11p110 to CDK11p58 and CDK11p46 can represent 
cell cycle re-entry and arrest as well as apoptotic pathways. The dysfunctional 
interplay of CDK11, and perhaps other CDK proteins that share homology with 
CDK11, with APP in AD and AD models points to the emerging roles of 
synaptic abnormalities, cell cycle re-entry, and microtubule impairment and 
transport, and it is the disruption of these associated cellular mechanisms that 
underlies the loss of neuronal connectivity and provides the basis of cognitive 
loss in AD [54].  
It is evident that in AD there is aberrant localization of nuclear proteins involved 
in cell cycle activation, including various cyclins. The inappropriate localization 
of nuclear proteins to the cytoplasm of neurons in AD may lead us to suspect  
a dysfunction in the nucleoplasmic transport mechanism of proteins, importins, 
and congruently the engine that enables proteins to be imported in and out of the 
nuclei, the GTPase RAN. RAN-GTP controls both MT micronucleation and plus 
end stabilization. In hippocampal neurons from AD patients importin α is 
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abnormally expressed [55], indicating impairment of microtubular transport. 
CDK11 localizes to spindle microtubules (MT) and centrosomes, and may bind 
to MT through an interaction with its substrate. In the absence of CDK11, MT 
are shorter, whereas spindle assembly takes a longer time to organize [26]. 
Given the notion that under normal function conditions CDK11 needs to be 
present in the nucleus of neuronal cells [20], both the loss of nuclear localization 
in AD brain sections and the increase in the cellular processes may correlate to 
failed attempts of these neurons to maintain a differentiated or quiescent state. 
This reinforces an old question raised in studies of mislocalization of many cell 
cycle markers and signal transduction molecules: why do these nuclear proteins 
accumulate in the cytoplasm in disease states? Is it an active or passive process? 
Is it a problem of nuclear-cytoplasm transport or a problem of decreased 
proteolytic activity of neurons during AD?  
In conclusion, alteration of CDK11 localization in specific cellular populations 
as well as in AD, and APP and Aβ-induced CDK11p110 expression in cell culture 
models, suggest key alterations in neuronal homeostasis in the disease. Further 
work will delineate the APP-CDK11 connection and its significance for the APP 
signaling pathway in the course of the disease.  
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